Posted on October 31st 2019
VANCOUVER, British Columbia–(BUSINESS WIRE)–#antibodies—AbCellera, a leader in therapeutic antibody discovery from natural immune systems, has appointed Dr. Michael Hayden to its Board of Directors. Dr. Hayden replaces former Director Andrew Booth, who recently transitioned to an executive role as AbCellera’s Chief Financial Officer.
“We are immensely pleased to have Dr. Hayden joining AbCellera’s Board of Directors,” said Dr. Carl Hansen, CEO of AbCellera. “Michael is one of the most prolific and effective people I have had the pleasure of knowing. Not only is he a world-renowned scientist, an accomplished serial entrepreneur, and an experienced pharma executive, he is also a leader of impeccable character and judgment. I look forward to working with Michael as we bring AbCellera to the next stage of growth.”
Dr. Hayden is the co-founder of five biotechnology companies: Prilenia Therapeutics, NeuroVir Therapeutics, Xenon Pharmaceuticals, Aspreva Pharmaceuticals, and 89Bio. From 2012 to 2017, Dr. Hayden served as Chief Scientific Officer and President of Global Research and Development at Teva Pharmaceutical Industries. During his tenure, 35 new products were approved, including many therapies related to the treatment of diseases of the central nervous system. Austedo, a drug for the treatment of chorea associated with Huntington’s disease, was the second molecule ever to be approved for the disease.
“AbCellera has established itself as the go-to discovery engine for therapeutic antibodies,” said Dr. Hayden. “The company has secured exciting partnerships in the life science industry that show confidence in its technology and science. I’m delighted to have the opportunity to share my experience with the management team and to contribute to the growth of the company.”
Dr. Hayden earned a Medical Doctorate and a PhD in Genetics from the University of Cape Town as a top graduate. He then completed a postdoctoral fellowship in Internal Medicine and Genetics at Harvard Medical School before entering a highly productive academic career.
Dr. Hayden’s research focuses on personalized medicine and genetic diseases, including lipoprotein disorders and Huntington’s disease. He is a Killam professor at the University of British Columbia, where he founded the Centre for Molecular Medicine and Therapeutics (CMMT). He is also a Canada Research Chair in Human Genetics and Molecular Medicine. With 900 publications and invited submissions, an h-index of 139, and over 79,000 citations, Dr. Hayden is the most cited author in the world for Huntington’s disease and ABCA1, a gene with major implications in atherosclerosis and diabetes.
Dr. Hayden has won multiple awards, including the Order of Canada (2010), the Canada Gairdner Wightman Award (2011) from the Gairdner Foundation, and The Diamond Jubilee Medal on behalf of HRH Queen Elizabeth II (2012). He was recognized as one of the 100 Most Inspiring People in pharma by PharmaVOICE in 2015 and was inducted into the Canadian Medical Hall of Fame in 2017. In a book by Ken McGoogan, Dr. Hayden was recognized as one of the 50 Canadians Who Changed the World.
About AbCellera Biologics Inc.
AbCellera is a privately held company that engages in partnerships to discover and develop next-generation therapeutic antibodies. AbCellera’s single-cell platform integrates end-to-end capabilities for therapeutic antibody discovery through a unique combination of technologies including proprietary immunizations, microfluidics, high-throughput imaging, genomics, deep computation, artificial intelligence, and laboratory automation. Ultra-deep screening of single B cells allows unprecedented access to natural immune responses, enabling rapid isolation of large and diverse panels of high-quality lead antibodies from any species, including humans. For more information, visit www.abcellera.com.
Kevin Heyries, PhD
Matias Marquez Interview
Matias Marquez founded Buyatab in 2008. He has since received numerous awards and recognition for his entrepreneurial success, including: being named a BC Business Top 30 Under 30 recipient in 2016; winner of the 2016 EY Entrepreneur of The YearRead More...
Braden Parker Interview
Braden Parker is co-founder of Casca Footwear, an innovative startup, developing all-day performance shoes for future builders. In the past year, Braden has moved from real-estate asset manager to co-founder of a bootstrapped venture looking to challenge the global footwearRead More... Braden Parker is co-founder of Casca Footwear, an innovative startup, developing all-day performance shoes for future builders. In the past year, Braden has moved from real-estate asset manager to co-founder of a bootstrapped venture looking to challenge the global footwear giants
Ilya Brotzky Interview
Ilya is the CEO and founder of VanHack. After graduating from Cornell University with a Degree in Applied Economics and Management, Ilya spent 4 years working in the Brazilian startup scene where he joined the country’s most successful early stageRead More...
Praveen Varshney Interview
Praveen Varshney has been a principal of Varshney Capital Corp., a Vancouver based merchant banking, venture capital and corporate advisory services firm, since 1991. He is a director or officer of various publicly traded companies including Mogo and Hempco FoodRead More...
Arran Stephens Interview
Arran Stephens was born in 1944 and was raised on Vancouver Island. His parents pioneered sustainable farming in the 1950’s and advised Arran to “leave the earth better than you found it.” After pursuing art and having several successful exhibitionsRead More...
Terry McBride Interview
Today we are with Terry McBride who is the current CEO of YYoga and one of the three founding members of the Nettwerk Music Group, which includes Nettwerk Productions (independent record label), Nettwerk Management (artist and producer management), Nettwerk OneRead More...